The PRIDE study conducted by Janssen Pharmaceuticals, compared paliperidone palmitate (INVEGA SUSTENNA®) with commonly prescribed oral antipsychotics in adults with schizophrenia who had prior involvement with the criminal justice system. Results showed that INVEGA SUSTENNA® reduced the risk of treatment failure (including psychiatric hospitalization, arrest/incarceration, and discontinuation for safety/efficacy reasons). The benefits were seen both in patients with and without substance use disorders, and no new safety concerns were identified.
To read the full article, click here.
Contributor: Johnson & Johnson
